Clinical Trials
9 trialsNCT04339062 2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00591734 2021-11-24
RAD001 Plus Bevacizumab in Metastatic Melanoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00474929 2019-08-20
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00521001 2017-08-14
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01252251 2017-08-01
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00976573 2017-04-04
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01637090 2017-01-12
CTCL
Boston Medical Center
Phase 2 Terminated
NCT01014351 2014-03-26
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
SCRI Development Innovations, LLC
Phase 2 Completed